[Ad Hoc Announcement Pursuant to Art. 53 LR] Roche Provides Update on Phase III PersevERA Study in ER-Positive Advanced Breast Cancer
March 10, 2026
March 10, 2026
BASEL, Switzerland, March 10 -- Roche, a biotech company, issued the following news release on March 9, 2026:
* * *
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
* persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed
* Giredestrant p . . .
* * *
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
* persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed
* Giredestrant p . . .